Furthermore, another study revealed that MTAP deletion results in accumulation of the metabolite 2-methylthioadenosine and promotes the synergism between inhibitors of PRMT5 and of type I PRMT (i.e., GSK3368715) in PDAC [79], a tumor type in which MTAP is frequently deleted. Here, PRMT5 is linked to neoplasm.